Edwards Net Receivables from 2010 to 2024

EW Stock  USD 72.07  0.52  0.73%   
Edwards Lifesciences Net Receivables yearly trend continues to be fairly stable with very little volatility. Net Receivables is likely to outpace its year average in 2024. During the period from 2010 to 2024, Edwards Lifesciences Net Receivables regression line of quarterly data had mean square error of 2614.2 T and geometric mean of  457,509,943. View All Fundamentals
 
Net Receivables  
First Reported
2000-03-31
Previous Quarter
834.4 M
Current Value
811.5 M
Quarterly Volatility
223.9 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Edwards Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Edwards Lifesciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 89.7 M, Interest Expense of 10.6 M or Selling General Administrative of 1.8 B, as well as many indicators such as Price To Sales Ratio of 4.36, Dividend Yield of 0.0 or PTB Ratio of 4.82. Edwards financial statements analysis is a perfect complement when working with Edwards Lifesciences Valuation or Volatility modules.
  
Check out the analysis of Edwards Lifesciences Correlation against competitors.

Latest Edwards Lifesciences' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Edwards Lifesciences Corp over the last few years. It is Edwards Lifesciences' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Edwards Lifesciences' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Slightly volatile
   Net Receivables   
       Timeline  

Edwards Net Receivables Regression Statistics

Arithmetic Mean501,063,000
Geometric Mean457,509,943
Coefficient Of Variation41.77
Mean Deviation174,853,867
Median462,200,000
Standard Deviation209,286,329
Sample Variance43800.8T
Range723.7M
R-Value0.97
Mean Square Error2614.2T
R-Squared0.94
Slope45,482,554
Total Sum of Squares613210.7T

Edwards Net Receivables History

2024878.7 M
2023836.9 M
2022699.1 M
2021664.9 M
2020602.8 M
2019599.1 M
2018537.3 M

About Edwards Lifesciences Financial Statements

Edwards Lifesciences investors use historical fundamental indicators, such as Edwards Lifesciences' Net Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Edwards Lifesciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Receivables836.9 M878.7 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Edwards Stock Analysis

When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.